稳定性心绞痛的调脂治疗PPT课件.ppt

;COURAGE研究证实药物治疗在稳定性冠心病治疗中的基石地位;*;*;*;*;*;*;;*;*;高危患者LDL-C小于100mg/dl依据来源于多项流行病学研究; ; ; ; ;;*;*;*;*LDL-C 100 mg/dl is the optimal target level set by the National Cholesterol Education Program (NCEP) ATP III. The other two LDL-C ranges were defined prior to randomization and were based on NCEP guidelines. Adapted from MRC/BHF Heart Protection Study Final Results. Presented at the European Atherosclerosis Society. Salzburg, Austria, July 2002 (www.ctsu.ox.ac.uk); Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults JAMA 2001;285:2486-2497.; ;稳定性冠心病LDL-C小于70mg/dl的可行性来自TNT与IDEAL的结果;TNT和IDEAL研究告诉我们什么？如何看待非血管原因死亡的增加和大剂量他汀的安全性; ; ;循证证据 = 高性价比 ?大剂量他汀在稳定性冠心病中应用的性价比需要进一步验证; ; ; ; ;FATS与HATS研究：HPS2的研究依据烟酸与他汀合用的治疗益处;MK-0524A 2g (+ 辛伐他汀 40 mg 或 依则麦布/辛伐他汀10/40 mg);